Perhaps i should have been more specific:
The potential of embryonic stem cell research. Many scientists believe that embryonic stem cell research may eventually lead to therapies that could be used to treat diseases that afflict approximately 128 million Americans. Treatments may include replacing destroyed dopamine-secreting neurons in a Parkinson's patient's brain; transplanting insulin-producing pancreatic beta cells in diabetic patients; and infusing cardiac muscle cells in a heart damaged by myocardial infarction. Embryonic stem cells may also be used to understand basic biology and to evaluate the safety and efficacy of new medicines.
That's potentially BIG business either gained or lost.
List of Benefits of Stem Cells to Human Patients
Adult Stem Cells v. Embryonic Stem Cellshttp://www.stemcellresearch.org/facts/treatments.htmForbes Magazine provided additional confirmation that
adult stem cell research is far more successful that embryonic stem cell experimentation. In their September 3, 2001 issue, page 36, they quoted an article printed in the Wall Street Journal Europe by Richard Miniter.
“Of the
15 US biotech companies solely devoted to developing cures using stem cells,
only two focus on embryos. Embryo stem cell research is at the drawing-board stage – not for lack of funds but for lack of promising research to finance. Venture capitalists have no agenda beyond making money; if they see embryo projects that are likely to bear fruit over the next five to seven years – the usual VC time horizon – they will fund them. That the market is speaking so loudly against embryo stem cell research probably explains why embryo researchers are so eager to reverse the ban on government funding.”
Diane Irving, Ph.D., a former professor of biology at Georgetown University and former biochemist with the National Cancer Institute, said, “
I have argued that adult stem cells are better because they are closer to the stage of differentiation than embryonic or fetal cells – therefore they do not have as long a distance to travel differentiation-wise as the younger cells. Therefore
there is far less of a chance for genetic errors to be accumulated in the implanted cells and less side effects for the patient to deal with.”
http://www.lifeissues.org/cloningstemcell/bradsarticle.htmlThese latest results show that the ES cells need to be genetically modified and extensive manipulation in vitro before they can be transplanted safely.
Direct transplant of ES cells are known to give rise to teratomas and uncontrollable cell proliferation. There is already evidence that
ES cells are genetically unstable in long term culture, and are especially prone to chromosomal abnormalities. The risks involved in using the cytomegalovirus promoter to drive over-expression of the transcription factor are undetermined. To avoid immune rejection, the ES cells have to be tissue-matched from a bank of stem cells created from ‘spare’ human embryos.
Otherwise, a special human embryo has to be created for the purpose, by transferring the patient’s genetic material into an empty egg, a procedure prone to failure and morally objectionable to many, including scientists.
By contrast, adult stem cells could be transplanted directly without genetic modification or pre-treatments. They simply differentiate according to cues from the surrounding tissues and
do not give uncontrollable growth or tumours. The adult stem cells
also show high degrees of genomic stability during culture. There is no problem with immune rejection because the cells can readily be isolated from the patients requiring transplant. And
there is no moral objection involved. Better yet, research can be directed towards encouraging adult stem cells to regenerate and repair damaged tissues in situ, without the need for cell isolation and in vitro expansion. By minimising intervention,
risks are reduced, as well as cost, making the treatment available to everyone and not just the rich.
http://www.i-sis.org.uk/stemcells2.php